肠道菌群与糖尿病:研究、转化与临床应用——2023年《Diabetes》《Diabetes Care》与《Diabetologia》专家论坛
本文总结由《Diabetes》《Diabetes Care》和《Diabetologia》组织的国际专家论坛的共识,论坛于2023年在德国汉堡举行的欧洲糖尿病研究协会年会上召开,与会者为肠道微生物组与代谢领域的临床医生和基础科学家。专家结论包括:肠道菌群可能参与2型糖尿病病理生理;菌群高度个体化是研究障碍,需大型队列和深度测序宏基因组方法;需个体内重复采样研究;未来需大量研究确定该知识对糖尿病诊断和治疗的适用性,并需新技术和改进的计算工具。
要点
- 肠道菌群可能参与2型糖尿病病理生理,微生物代谢产物与疾病正负相关。
- 菌群高度个体化是主要研究障碍,需大型队列和深度测序宏基因组方法。
- 单时间点采样遗漏个体内菌群动态,未来需个体内重复测量研究。
核心结论
- 肠道菌群可能参与2型糖尿病病理生理,但菌群高度个体化,需大型队列和深度测序宏基因组方法评估关联与因果。
研究设计与样本
- 国际专家论坛,由《Diabetes》《Diabetes Care》和《Diabetologia》组织,于2023年在德国汉堡举行的欧洲糖尿病研究协会年会上召开,参与者为肠道微生物组与代谢领域的临床医生和基础科学家。
主要发现
- 微生物产生的代谢产物与2型糖尿病正相关和负相关,人类孟德尔随机化研究揭示了菌群功能(如丁酸产生基因)与糖代谢的机制联系。
- 菌群高度个体化是主要研究障碍,需大型队列和深度测序宏基因组方法进行稳健的关联与因果评估。
- 单时间点采样遗漏个体内菌群动态,未来需个体内重复测量研究。
- 未来需大量研究确定不断扩展的知识对糖尿病诊断和治疗的适用性,新技术和改进的计算工具对实现该目标很重要。
临床怎么用
- 原文未据此给出推荐。
局限性
- 菌群高度个体化是主要研究障碍,需大型队列和深度测序宏基因组方法进行稳健评估。
- 单时间点采样遗漏个体内菌群动态,未来需个体内重复测量研究。
- 未来需大量研究确定该知识对糖尿病诊断和治疗的适用性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
This article summarizes the state of the science on the role of the gut microbiota (GM) in diabetes from a recent international expert forum organized by Diabetes, Diabetes Care, and Diabetologia, which was held at the European Association for the Study of Diabetes 2023 Annual Meeting in Hamburg, Germany. Forum participants included clinicians and basic scientists who are leading investigators in the field of the intestinal microbiome and metabolism. Their conclusions were as follows: 1) the GM may be involved in the pathophysiology of type 2 diabetes, as microbially produced metabolites associate both positively and negatively with the disease, and mechanistic links of GM functions (e.g., genes for butyrate production) with glucose metabolism have recently emerged through the use of Mendelian randomization in humans; 2) the highly individualized nature of the GM poses a major research obstacle, and large cohorts and a deep-sequencing metagenomic approach are required for robust assessments of associations and causation; 3) because single-time point sampling misses intraindividual GM dynamics, future studies with repeated measures within individuals are needed; and 4) much future research will be required to determine the applicability of this expanding knowledge to diabetes diagnosis and treatment, and novel technologies and improved computational tools will be important to achieve this goal.
引用
- Byndloss M, Devkota S, Duca F, et al. The Gut Microbiota and Diabetes: Research, Translation, and Clinical Applications-2023 Diabetes, Diabetes Care, and Diabetologia Expert Forum. Diabetes Care. 2024. PMID: 38996003. doi:10.2337/dci24-0052
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。